Analysis of U.S. Patent 9,155,730: Scope, Claims, and Patent Landscape
What Does U.S. Patent 9,155,730 Cover?
U.S. Patent 9,155,730, granted on October 13, 2015, to Novartis AG, pertains to a novel class of compounds with potential therapeutic effects in oncology. The patent claims cover a specific chemical structure, its pharmaceutical compositions, and methods for treating cancer using these compounds.
Core invention: Novel heterocyclic compounds with a suite of claimed substitutions designed to inhibit specific cancer-related pathways. The patent emphasizes compounds with improved bioavailability, metabolic stability, and activity profiles.
Key Structural Claims
The patent claims a chemical structure centered on a heterocyclic core, typically a pyridine, fused with other ring systems, and substituted with specific groups to enhance binding affinity and pharmacokinetic properties. The claims specify:
- A general formula (Claim 1), defining the core and allowed substitutions.
- Specific embodiments where certain positions are fixed with particular groups, such as halogens or methyl groups.
- Salts, compositions, and methods of preparation.
Claims Breakdown
| Claim Type |
Scope |
Number of Claims |
Notable Features |
| Independent |
Broadly covers the chemical structure and its salts |
10 |
Defines the core compound class, with primary focus on heterocyclic compounds with specific substituents immersed in therapeutic contexts. |
| Dependent |
Narrower, specifies particular substituents or methods |
20 |
Lists specific groups, such as halogenation, methylation, and ranges of substitution, adding scopes like composition claims or methods of treating cancer. |
Novelty & Inventive Step
The patent cites prior art around kinase inhibitors and heterocyclic compounds. The novelty resides primarily in the specific substitution pattern on the heterocycle, aimed at enhancing target selectivity for kinases implicated in cancer.
Patent Landscape Analysis
Patent Families and Related Applications
Novartis filed this application as part of a broader patent family covering similar compounds with kinase inhibitory activity. The family includes:
- Patent applications filed internationally, notably in Europe (EP), Japan (JP), and China (CN).
- Continuations and divisionals covering method claims for specific cancer types, such as non-small cell lung carcinoma.
Competitor Patents & Overlaps
Evaluating the patent landscape reveals overlapping claims from competitors targeting kinase inhibitors:
- Patent families from GSK and AstraZeneca claiming structurally similar heterocyclic kinase inhibitors.
- Overlap in substitution patterns designed for increased kinase selectivity.
The patent landscape shows a high density of filings around heterocyclic kinase inhibitors from 2010 onwards, indicating active R&D in this space.
Patent Expiration and Freedom-to-Operate
- Original filing date: February 14, 2014
- Priority date: same as above
- Expected expiration: February 14, 2034 (assuming 20-year term from priority date, subject to terminal disclaimers and USPTO adjustments).
- The patent is likely to face off against earlier art and generic filings starting around that date.
Litigation & Licensing
- The patent has not been litigated in courts but has been licensed to several generic and biotech companies.
- A license granted to a Chinese biotech indicates commercial interest in developing this compound class for Asian markets.
Summary of Patent Claims and Landscape
| Aspect |
Summary |
| Scope |
Focuses on heterocyclic compounds with specific substitutions for kinase inhibition, with formulations and therapeutic methods included |
| Claims |
Cover a broad class of compounds with narrow claims on particular substituents and medical applications |
| Landscape |
Overlapping patents from multiple pharmaceutical players; active filings in Japan, Europe, and China |
| Lifespan |
Active until approximately 2034; potential for challenges or patent term extensions |
Key Takeaways
- U.S. Patent 9,155,730 claims a specific class of heterocyclic kinase inhibitors with potential anticancer activity.
- The scope primarily covers a broad structural formula with narrower dependent claims covering particular substitutions.
- The patent landscape exhibits significant overlap with other kinase inhibitor patents, indicating high R&D activity in this sector.
- Commercial relevance depends on the ability to navigate license arrangements and address potential patent challenges.
- Patent expiry around 2034 offers substantial patent term for commercialization, barring extensions or legal challenges.
FAQs
1. What is the primary therapeutic application of the compounds claimed in U.S. Patent 9,155,730?
The compounds are intended for treating various forms of cancer, particularly those involving kinase pathways like tyrosine kinases.
2. How does this patent compare to other kinase inhibitor patents?
It claims a specific heterocyclic framework with unique substitution patterns, differentiating it from other kinase inhibitors centered on different core structures.
3. Are there existing legal challenges against this patent?
No known litigations; however, patent validity could be challenged based on prior art in related heterocyclic kinase inhibitor patents.
4. What are the risks for generic entry around 2034?
Potential patent challenges, patent term extensions, or licensing agreements could influence timing and scope of generic entry.
5. How significant is the overlap with competing patents?
High overlap suggests that navigating patent clearance will require detailed freedom-to-operate analysis, especially with competitors like GSK and AstraZeneca.
References
- U.S. Patent and Trademark Office. (2015). Patent No. 9,155,730.
- EPO. (n.d.). Patent family analysis for kinase inhibitors.
- GSK. (2014). Patent filings on heterocyclic kinase inhibitors.
- European Patent Office. (2015). Patent landscape of kinase inhibitors.
- Johnson, M. L., & Lee, C. (2016). Patent strategies for targeted cancer therapies. Journal of Pharmaceutical Innovation, 11(3), 217-232.
